AAAAAA

   
Results: 1-13 |
Results: 13
RADIOIMMUNOTHERAPY OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) WITH IDEC-Y2B8 (90)YTTRIUM ANTI-CD20 MONOCLONAL-ANTIBODY
Authors: WISEMAN G WITZIG T WHITE CA SOLINGER A GORDON L RAUBITSCHEK A EMMANOUILIDES C GUTHEIL J PARKER E CHINN P GRILLOLOPEZ A
Citation: G. Wiseman et al., RADIOIMMUNOTHERAPY OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) WITH IDEC-Y2B8 (90)YTTRIUM ANTI-CD20 MONOCLONAL-ANTIBODY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(1), 1998, pp. 22-22
PHASE-I RADIOIMMUNOTHERAPY TRIAL EVALUATING (90)YTTRIUM LABELED ANTI-CEA CHIMERIC T84.66 IN PATIENTS WITH METASTATIC CEA-PRODUCING MALIGNANCIES
Authors: WONG J CHU D YAMAUCHI D ODOMMARYON T WILLIAMS L LIU A WILCYZNSKI S WU A SHIVELY J DOROSHOW J RAUBITSCHEK A
Citation: J. Wong et al., PHASE-I RADIOIMMUNOTHERAPY TRIAL EVALUATING (90)YTTRIUM LABELED ANTI-CEA CHIMERIC T84.66 IN PATIENTS WITH METASTATIC CEA-PRODUCING MALIGNANCIES, International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 205-205
IDEC-Y2B8 (Y-90 CONJUGATED ANTI-CD20) DOSIMETRY CALCULATED FROM IN-111 ANTI-CD20 IN PATIENTS WITH LOW AND INTERMEDIATE GRADE B-CELL NON-HODGKINS-LYMPHOMA (NHL) EMPHASIS ON BONE-MARROW (BM)
Authors: WISEMAN GA SOLINGER AM GRILLOLOPEZ A STABIN M DUNN WL WITZIG TE SPIES S GORDON L RAUBITSCHEK A MARGOLIN K KARVELIS K JANAKIRAMAN N SILVERMAN DH EMMANOULIDES C ROYSTON I CHINN P PARKER E CARTER W WHITE CA
Citation: Ga. Wiseman et al., IDEC-Y2B8 (Y-90 CONJUGATED ANTI-CD20) DOSIMETRY CALCULATED FROM IN-111 ANTI-CD20 IN PATIENTS WITH LOW AND INTERMEDIATE GRADE B-CELL NON-HODGKINS-LYMPHOMA (NHL) EMPHASIS ON BONE-MARROW (BM), Blood, 90(10), 1997, pp. 2273-2273
IDEC-Y2B8 (90)YTTRIUM ANTI-CD20 RADIOIMMUNOTHERAPY OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) - INTERIM RESULTS OF A PHASE I II TRIAL/
Authors: WITZIG T WISEMAN C WHITE CA SOLINGER A GORDON L RAUBITSCHEK A EMMANOULIDES C ROYSTON I PARKER E CHINN P GRILLOLOPEZ A
Citation: T. Witzig et al., IDEC-Y2B8 (90)YTTRIUM ANTI-CD20 RADIOIMMUNOTHERAPY OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) - INTERIM RESULTS OF A PHASE I II TRIAL/, Blood, 90(10), 1997, pp. 2606-2606
MINIBODY - A NOVEL ENGINEERED ANTICARCINOEMBRYONIC ANTIGEN-ANTIBODY FRAGMENT (SINGLE-CHAIN FV-C(H)3) WHICH EXHIBITS RAPID, HIGH-LEVEL TARGETING OF XENOGRAFTS
Authors: HU SZ SHIVERY L RAUBITSCHEK A SHERMAN M WILLIAMS LE WONG JYC SHIVELY JE WU AM
Citation: Sz. Hu et al., MINIBODY - A NOVEL ENGINEERED ANTICARCINOEMBRYONIC ANTIGEN-ANTIBODY FRAGMENT (SINGLE-CHAIN FV-C(H)3) WHICH EXHIBITS RAPID, HIGH-LEVEL TARGETING OF XENOGRAFTS, Cancer research, 56(13), 1996, pp. 3055-3061
BREAST-TUMOR XENOGRAFT TARGETING AND THERAPY STUDIES USING RADIOLABELED CHIMERIC ANTI-CEA MONOCLONAL-ANTIBODY T84.66
Authors: ESTEBAN JM RAUBITSCHEK A FELDER B WILLIAMS LE WONG JYC SHIVELY JE
Citation: Jm. Esteban et al., BREAST-TUMOR XENOGRAFT TARGETING AND THERAPY STUDIES USING RADIOLABELED CHIMERIC ANTI-CEA MONOCLONAL-ANTIBODY T84.66, Oncology Reports, 2(2), 1995, pp. 237-242
GAMMA-INTERFERON ADMINISTRATION AFTER Y-90 RADIOLABELED ANTIBODY THERAPY - SURVIVAL AND HEMATOPOIETIC TOXICITY STUDIES
Authors: THOMAS GE ESTEBAN JM RAUBITSCHEK A WONG JYC
Citation: Ge. Thomas et al., GAMMA-INTERFERON ADMINISTRATION AFTER Y-90 RADIOLABELED ANTIBODY THERAPY - SURVIVAL AND HEMATOPOIETIC TOXICITY STUDIES, International journal of radiation oncology, biology, physics, 31(3), 1995, pp. 529-534
A FACILE, WATER-SOLUBLE METHOD FOR MODIFICATION OF PROTEINS WITH DOTA- USE OF ELEVATED-TEMPERATURE AND OPTIMIZED PH TO ACHIEVE HIGH SPECIFIC ACTIVITY AND HIGH CHELATE STABILITY IN RADIOLABELED IMMUNOCONJUGATES
Authors: LEWIS MR RAUBITSCHEK A SHIVELY JE
Citation: Mr. Lewis et al., A FACILE, WATER-SOLUBLE METHOD FOR MODIFICATION OF PROTEINS WITH DOTA- USE OF ELEVATED-TEMPERATURE AND OPTIMIZED PH TO ACHIEVE HIGH SPECIFIC ACTIVITY AND HIGH CHELATE STABILITY IN RADIOLABELED IMMUNOCONJUGATES, Bioconjugate chemistry, 5(6), 1994, pp. 565-576
RADIOLABELED CHX(B)-2E4 IS STABLE IN-VIVO AND IS A SUITABLE IMMUNOCONJUGATE FOR TESTING ALPHA-PARTICLE-EMITTING BISMUTH RADIONUCLIDES IN INTERLEUKIN-2 RECEPTOR TARGETED IMMUNOTHERAPY
Authors: TIFFANY LJ DOBBS D GARMESTANI K RAUBITSCHEK A TINUBU A BRECHBIEL MW GOFFMAN T GANSOW OA WALDMANN TA KOZAK RW
Citation: Lj. Tiffany et al., RADIOLABELED CHX(B)-2E4 IS STABLE IN-VIVO AND IS A SUITABLE IMMUNOCONJUGATE FOR TESTING ALPHA-PARTICLE-EMITTING BISMUTH RADIONUCLIDES IN INTERLEUKIN-2 RECEPTOR TARGETED IMMUNOTHERAPY, Antibody immunoconjugates, and radiopharmaceuticals, 7(2), 1994, pp. 99-115
CONTINUOUS-INFUSION CHEMOTHERAPY AS A RADIATION-ENHANCING AGENT FOR YTTRIUM-90-RADIOLABELED MONOCLONAL-ANTIBODY THERAPY OF A HUMAN TUMOR XENOGRAFT
Authors: REMMENGA SW COLCHER D GANSOW O PIPPEN CG RAUBITSCHEK A
Citation: Sw. Remmenga et al., CONTINUOUS-INFUSION CHEMOTHERAPY AS A RADIATION-ENHANCING AGENT FOR YTTRIUM-90-RADIOLABELED MONOCLONAL-ANTIBODY THERAPY OF A HUMAN TUMOR XENOGRAFT, Gynecologic oncology, 55(1), 1994, pp. 115-122
CONTINUOUS-INFUSION CHEMOTHERAPY AS A RADIATION-ENHANCING AGENT FOR YTTRIUM-90-RADIOLABELED MONOCLONAL-ANTIBODY THERAPY OF A HUMAN TUMOR XENOGRAFT
Authors: REMMENGA SW COLCHER D GANSOW O PIPPEN CG RAUBITSCHEK A
Citation: Sw. Remmenga et al., CONTINUOUS-INFUSION CHEMOTHERAPY AS A RADIATION-ENHANCING AGENT FOR YTTRIUM-90-RADIOLABELED MONOCLONAL-ANTIBODY THERAPY OF A HUMAN TUMOR XENOGRAFT, Gynecologic oncology, 55(1), 1994, pp. 115-122
DIFFERENTIAL EXPRESSION OF CYCLIN PROTEINS IN CONNECTION WITH CELL-CYCLE CHANGES AND WITH STEM-CELL CONTENT IN REGENERATING BONE-MARROW
Authors: HEGYI E BOLEN J MARYON T WONG J RAUBITSCHEK A
Citation: E. Hegyi et al., DIFFERENTIAL EXPRESSION OF CYCLIN PROTEINS IN CONNECTION WITH CELL-CYCLE CHANGES AND WITH STEM-CELL CONTENT IN REGENERATING BONE-MARROW, Blood, 84(10), 1994, pp. 10000567-10000567
CHANGES IN CELL CYCLING AND OF CYTOKINE LEVELS ARE RESPONSIBLE FOR THE RADIOPROTECTIVE EFFECT OF 5-FU
Authors: HEGYI E LIU M ESTEBAN J YAN X WONG J RAUBITSCHEK A
Citation: E. Hegyi et al., CHANGES IN CELL CYCLING AND OF CYTOKINE LEVELS ARE RESPONSIBLE FOR THE RADIOPROTECTIVE EFFECT OF 5-FU, Blood, 82(10), 1993, pp. 10000483-10000483
Risultati: 1-13 |